-
Turoctocog alfa pegol
- names:
Turoctocog alfa pegol
- CAS号:
1309086-46-1
MDL Number: - MF(分子式): MW(分子量):
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| DBK502205-500mg | 500mg | ¥ 0.00 | ¥ 0.00 | Get quote | ¥ 0.00 | |||
| DBK502205-100mg | 100mg | ¥ 0.00 | ¥ 0.00 | Get quote | ¥ 0.00 |
| 中文别名 | Turoctocog alfa pegol |
| 英文别名 | Turoctocog alfa pegol |
| CAS号 | 1309086-46-1 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | |
| 分子量 Molecular Weight | |
| 溶解度Solubility | |
| 性状 | NA |
| 储藏条件 Storage conditions |
Turoctocog alfa pegol使用注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品的移液枪头需及时更换,必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸,并无风处取药和称量以免扬撒,试剂的容器使用前务必确保干净,并消毒。
5.取药品时尽量采用多个药勺分别使用,使用后清洗干净。
6.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染。
大规格定制:定制产品请将信息发送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品的移液枪头需及时更换,必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸,并无风处取药和称量以免扬撒,试剂的容器使用前务必确保干净,并消毒。
5.取药品时尽量采用多个药勺分别使用,使用后清洗干净。
6.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染。
大规格定制:定制产品请将信息发送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
| 产品说明 | Organic Acids |
| Introduction | |
| Application1 | The principal characteristic that defines hemophilia A is the limited presence or complete deficiency of human clotting factor VIII in the body5. Subsequently, because factor VIII is a critical component that is essential for the extrinsic tissue factor pathway of the blood coagulation cascade process to proceed, individuals with hemophilia A ultimately experience increased bleeding - in comparison to individuals without a factor VIII deficiency - after injury or any kind of medical procedure5. Such increased bleeding can be heavy and/or fatal and may occur due to minimal injury or even when there is no injury whatsoever - in which case the bleeding is spontaneous5. Furthermore, excessive bleeds that bleed into muscles, organs, and joints are also associated with dangerous complications and regular pain5.The turoctocog alfa pegol (N8-GP) drug is consequently recombinant factor VIII (rFVIII) in which specific site-directed glycoPEGylation has been performed in an effort to increase the half-life of the rFVIII moiety without altering its hemostatic activity1,2. In particular, the general rFVIII component of N8-GP is turoctocog alfa, a human coagulation factor VIII (rDNA), with a truncated B-domain1,2. This glycoprotein has the same structure as human clotting factor VIII when activated, and also possesses post-translational modifications that are similar to those of the plasma-derived molecule1,2.In blood, factor VIII predominantly circulates in a stable non-covalent complex with von Willebrand factor (vWF)3,6. Concurrently, the tyrosine sulfation site present at the Tyr1680 (native full length) position, which is important for binding to vWF, has been found to be fully sulfated in the turoctocog alfa molecule1,2. Subsequently, when infused into a hemophilia patient, this rFVIII binds to endogenous vWF in the patient’s circulation1,2. The resultant factor VIII/vWF complex consists of two molecules (factor VIII and vWF) with different physiological functions1,2,3,6. Factor VIII is activated by thrombin (factor IIa)1,2,5. Activated factor VIII acts as a co-factor for activated factor IX, accelerating the conversion of factor X to activated factor X5. Activated factor X converts prothrombin into thrombin5. Thrombin then converts fibrinogen into fibrin and a clot can be formed5. Turoctocog alfa pegol consequently functions predominantly as factor VIII replacement therapy for patients with factor VIII deficient hemophilia A.Finally, the particular N8-GP molecule has a 40-kDa polyethylene glycol (PEG) attached to a specificO-glycan in the truncated B-domain of the general turoctocog alfa rFVIII structure1,2. Upon activation by thrombin, this B-domain possessing the pegylation is cleaved away, leaving active rFVIIIa - which as discussed above, is highly similar to and elicits the same blood clotting activities as native factor VIII1,2. Subsequently, the PEG group of N8-GP ultimately serves to extend the half-life of the overall drug molecule in the body. As an inert chemical, the PEG group prolongs N8-GP's half-life by acting like an obstructive 'cloud' around the rFVIII molecule to which it is attached12. Since the PEG group is generally too large to be cleared by the kidneys and does not bind particularly well with the clearance receptors that typically eliminate endogenous factor VIII, N8-GP demonstrates a longer half-life than the general turoctocog alfa rFVIII structure12.TargetActionsOrganismACoagulation factor IXactivatorHumansACoagulation factor XactivatorHumansAProthrombinbinderHumans |
| Application2 | |
| Application3 |
| 警示图 | |
| 危险性 | |
| 危险性警示 | warning |
| 安全声明 | |
| 安全防护 | |
| 备注 | 实验过程中防止吸入、食如,做好安全防护 |
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


